Press Enter to search · Esc to close
New real-world data is shifting the GLP-1 conversation from 'does it work' to 'how to use it without getting hurt.' Here's what the latest evidence actually says.
AstraZeneca's once-daily small molecule posts placebo-controlled weight-loss data in The Lancet — and hints at a future where the obesity revolution doesn't require a needle.
A massive new target-trial emulation hints that semaglutide and tirzepatide may do more than shrink waistlines — they may quietly cut the odds of obesity-driven cancers. Here's what the data actually say.
A phase 3 trial of a glucagon/GLP-1 dual agonist lands alongside a semaglutide biosimilar and new cardiometabolic signals — incretin therapy is outgrowing the obesity box.
Two simultaneous Lancet trials test Novo Nordisk's next-generation incretin against the current heavyweight. Here's what a busy 40-year-old should actually take from the readout.
GLP-1s deliver durable fat loss and metabolic wins — but a maturing evidence base is also flagging ocular signals and structural changes worth knowing before you pin or pass.
A 2026 systematic review reframes the pre-anesthesia question for semaglutide users — less about pausing the drug, more about clearing the stomach and checking it with ultrasound.
Semaglutide reshaped the conversation around obesity. The next round of data — from skeletal muscle to intracranial pressure to oral small molecules — is reshaping what comes next.
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
Semaglutide's clinical footprint is widening fast — new data hint at off-target wins, real-world rescues, and a sharpening list of who should pause before the pen.